RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01034-wThree randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research